Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases

Chemistry and Physics of Lipids

Volumn 128, Issue 1-2, 2004, Pages 117-124

  Montine, Kathleen S ^a   Quinn, Joseph F ^b   Zhang, Jing ^a   Fessel, Joshua P ^c   Roberts II, L Jackson ^c   Morrow, Jason D ^c   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer; Huntington; Isofurans; Isoprostanes; Neuroprostanes; Parkinson

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; FURAN DERIVATIVE; ISOPROSTANE DERIVATIVE;

ALZHEIMER DISEASE; BRAIN LEVEL; CEREBROSPINAL FLUID LEVEL; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; ISOMERIZATION; LABORATORY DIAGNOSIS; LIPID BRAIN LEVEL; LIPID PEROXIDATION; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; TISSUE DISTRIBUTION;

EID: 0842346368     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2003.10.010     Document Type: Review

References (50)

1. Ando Y., Brannstrom T., Uchida K., Nyhlin N., Nasman B., Suhr O., Yamashita T., Olsson T., Salhy M., Uchino M., Ando M. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156:1998;172-176.
2. Biaggioni I., Robertson D., Haile V., Jones M. The anemia of autonomic failure: evidence for sympathetic modulation of erythropoiesis in humans and reversal with recombinant erythropoietin. Ann. Intern. Med. 121:1994;181-186.
3. Butterfield D., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7:2001;548-554.
4. Castellani R.J., Perry G., Siedlak S.L., Nunomura A., Shimohama S., Zhang J., Montine T., Sayre L.M., Smith M.A. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett. 319:2002;25-28.
5. Duda J.E., Giasson B.I., Mabon M.E., Lee V.M., Trojanowski J.Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 52:2002;205-210.
6. Farber, J.L., 1995. Mechanisms of cell injury. In: Craighead, J.E. (Ed.), Mechanisms of Cell Injury. Mosby-Year Book Inc., St. Louis, pp. 287-302.
7. Feillet-Coudray C., Tourtauchaux R., Niculescu M., Rock E., Tauveron I., Alexandre-Gouabau M.C., Rayssiguier Y., Jalenques I., Mazur A. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic. Biol. Med. 27:1999;463-469.
8. Fessel J., Porter N., Moore K., Sheller J., Roberts L. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc. Natl. Acad. Sci. U.S.A. 99:2002;16713-16718.
9. Fessel, J.P., Hulette, C., Powell, S., Roberts, L.J. 2nd, Zhang, J. 2003. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J. Neurochem 85, 645-650.
10. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989.
11. Gutteridge, J.M.C., Westermarck, T., Halliwell, B., 1986. Oxygen radical damage in biological systems. In: Johnson, J.E., Walford, R., Harman, D., Miquel, J. (Eds.), Oxygen Radical Damage in Biological Systems. Alan R. Liss, New York, pp. 99-139.
12. Lovell M., Ehmann W., Butler S., Markesbery W. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
13. Lovell M., Ehmann W., Mattson M., Markesbery W. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging. 18:1997;457-471.
14. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging. 22:2001;187-194.
15. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging. 19:1998;33-36.
16. Mattson M.P. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci. 20:1998;53-57.
17. McGrath L.T., McGleenon B.M., Brennan S., McColl D., Mcllroy S., Passmore A.P. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. Q. J. Med. 94:2001;485-490.
18. Montine K.S., Olson S.J., Amarnath V., Whetsell W.O., Graham D.G., Montine T.J. Immunochemical detection of 4-hydroxynonenal adducts in Alzheimer's disease is associated with APOE4. Am. J. Pathol. 150:1997a;437-443.
19. Montine K.S., Kim P.J., Olson S.J., Markesbery W.R., Montine T.J. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropathol. Exp. Neurol. 56:1997b;866-871.
20. Montine K., Reich E., Olson S.J., Markesbery W.R., Montine T. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer's disease is associated with APOE genotype. J. Neuropathol. Exp. Neurol. 57:1998a;415-425.
21. 2-isoprostanes are increased in Alzheimer's disease. Ann. Neurol. 44:1998b;410-413.
22. 2-isoprostane concentration in probable Alzheimer's disease. Neurology. 52:1999a;562-565.
23. Montine T.J., Beal M.F., Robertson D., Cudkowicz M.E., Biaggioni I., O'Donnell H., Zackert W.E., Roberts L.J., Morrow J.D. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology. 52:1999b;1104-1105.
24. Montine T.J., Markesbery W.R., Zackert W., Sanchez S.C., Roberts L.J., Morrow J.D. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles, or with APOE genotype in Alzheimer's disease patients. Am. J. Pathol. 155:1999c;863-868.
25. 2 levels in patients with probable Alzheimer's disease. Neurology. 53:1999d;1495-1498.
26. 2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Ann. Neurol. 48:2000;950.
27. 2-isoprostane concentrations in patients with Alzheimer's disease other dementias and age-matched controls. Arch. Pathol. Lab. Med. 125:2001;510-512.
28. Montine T., Neely M., Quinn J., Beal M., Markesbery W., Roberts L., Morrow J. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 33:2002a;620.
29. 4-neuroprostanes are not increased in Alzheimer's disease. Ann. Neurol. 52:2002b;175-179.
30. Moore K., Roberts L.J. Measurement of lipid peroxidation. Free Radic. Res. 28:1998;659-671.
31. Morrow J., Hill K., Burk R., Nammour T., Badr K., Roberts L. A series of prostaglandin-like compounds produced in vivo in humans by a non-cyclooxygenase free radical catalyzed mechanism. Proc. Natl. Acad. Sci. U.S.A. 87:1990;9383-9387.
32. 2-isoprostanes) in smokers. N. Engl. J. Med. 332:1995;1198-1203.
33. Morrow J.D., Roberts L.J., Daniel V.C., Awad J.A., Mirochnitchenko O., Swift L.L., Burk R.F. Comparison of formation of D2/E2-isoprostanes and F2-isoprostanes in vitro and in vivo-effects of oxygen tension and glutathione. Arch. Biochem. Biophys. 353:1998;160-171.
34. Nourooz-Zadeh J., Liu E.H., Yhlen B., Anggard E.E., Halliwell B. F4-isoprostanes as specific marker of docosahexaenoic acid production in Alzheimer's disease. J. Neurochem. 72:1999;734-740.
35. Orth M., Schapira A. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40:2002;533-541.
36. Picklo M.J., Olson S.J., Markesbery W.R., Montine T.J. Expression and activities of aldo-keto oxidoreductases in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 60:2001;686-695.
37. Porter N.A., Caldwell S.E., Mills K.A. Mechanisms of free radical oxidation of unsaturated lipids. Lipids. 30:1995;277-290.
38. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12:1998;1777-1784.
39. Pratico D., Clack C.M., Lee V.M.Y., Trojanowski J.Q., Rokach J., FitzGerald G. Increased 8,12-iso-iPF2a-IV in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48:2000;809-812.
40. Reich E., Markesbery W., Roberts L. II, Swift L., Morrow J., Montine T. Brain regional quantification of F-ring and D/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am. J. Pathol. 158:2001;293-297.
41. Roberts L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., Detbarn W.D., Morrow J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273:1998;13605-13612.
42. Salem, N., Kim, H.Y., Yergey, J.A., 1986. Docosahexaenoic acid: membrane function and metabolism. In: Simopoulos, A.P., Kifer, R.R., Martin, R.E. (Eds.), Docosahexaenoic Acid: Membrane Function and Metabolism. Academic Press, New York, pp. 263-317.
43. Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer disease. J. Neurochem. 68:1997;2092-2097.
44. Shelley M.L. 4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 25:1998;169-174.
45. Sidell K.R., Olson S.J., Ou J.J., Zhang Y., Amarnath V., Montine T.J. Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. J. Neurochem. 79:2001;510-521.
46. Sidell K.R., Montine K.S., Picklo M.J. Sr., Olson S.J., Amamath V., Montine T.J. Mercapturate metabolism of 4-hydroxy-2-nonenal in rat and human cerebrum. J. Neuropathol. Exp. Neurol. 62:2003;146-153.
47. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature. 382:1996;120-121.
48. Smith M.A., Sayre L.M., Anderson V.E., Harris P.L., Beal M.F., Kowall N., Perry G. Cytochemical demonstration of oxidative damage in Alzheimer's disease by immunochemical enhancement of the carbonyl reaction with 2,4- dinitrophenylhydrazine. J. Histochem. Cytochem. 46:1998;731-735.
49. Waddington E., Croft K., Clarnette R., Mori T., Martins R. Plasma F2-isoprostane levels are increased in Alzheimer's disease: evidence of increased oxidative stress in vivo. Alzheimer's Rep. 2:1999;277-282.
50. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 93:1995;2696-2701.